Departmental Affiliations
Center & Institute Affiliations
Katya Tsaioun, PhD, MS, leads international multi-stakeholder efforts to establish evidence-based methodologies and practices in translational research to inform regulatory decisions.
Research Interests
evidence-based methodologies; evidence-based toxicology; translational research; in silico; in vitro
Additional Links
Experiences & Accomplishments
Dr. Tsaioun is a Director of Evidence-based Toxicology Collaboration at Johns Hopkins Bloomberg School of Public Health, where she leads international multi-stakeholder efforts to establish evidence-based methodologies and practices in translational research to inform regulatory decisions. The focus of Dr. Tsaioun’s career has been on translation of scientific innovations into policies and technologies enabling improvements in public health. She spent almost two decades in pharmaceutical industry leading translational drug-discovery teams, subsequently founding her company, Apredica, which became a leader in commercializing de-risking technologies.
After a successful acquisition of Apredica by Cyprotex, PLC (now Evotec), she served as a CSO and Board member in the merged public company. Dr. Tsaioun is serving on advisory boards and review committees of a number of governmental, commercial and non-profit organizations.
She earned her PhD in Human Nutrition Science from Tufts University Friedman School of Nutrition Science and Policy and completed post-doctoral training in neurochemistry at Harvard Medical School